
MindBio
Therapeutics

Important Notice.

This Investor Presentation Document (**IPD**) dated 14 June 2021 is not a document lodged with ASIC.

This IPD, has been prepared by MindBio Therapeutics Pty Ltd, a wholly owned subsidiary of Blackhawk Growth Corp (the "Company") for the purpose of providing certain financial and business information to potential investors.

This IPD is being provided to potential investors on the basis that they are a sophisticated investor or professional investor for the purposes of Section 708 of the Corporations Act. If you are not a sophisticated investor or professional investor for the purposes of Section 708 of the Corporations Act, any application that you make to acquire Shares in the Company will not be accepted by the Company unless the Company is otherwise satisfied you are a person to whom securities may be issued without disclosure under one of the other exemptions in Section 708 of the Corporations Act. In reading and accepting this IPD, the recipient agrees for itself and its related bodies corporate and their respective directors, officers, employees, agents, representatives and advisers (together the "Recipient") that it is provided on the terms and conditions of this important Notice.

You must provide a certificate certifying that you are a sophisticated investor or professional investor for the purposes of Section 708 of the Corporations Act (or evidence that you fall under one of the other exemptions in Section 708 of the Corporations Act) before any such application will be considered. A pro-forma certificate accompanies this IPD, and must be included with any application for Shares.

Important Document

It is Important that you carefully read this IPD in its entirety before deciding to invest in the Company and, in particular, that you consider the risk factors that could affect the financial performance of the Company and your investment in the Company. You should carefully consider these factors in light of your personal circumstances (including financial and taxation issues) and seek professional advice from your accountant, lawyer or other professional adviser before deciding whether to invest.

No recommendation

This IPD is not to be considered as a recommendation by the Company or any of its directors, officers, employees, agents or advisers that any Recipient invest in the Company, or that this investment is a suitable investment for the Recipient. The Recipient should conduct and rely upon its own investigation and analysis of the information in this IPD and other matters that may be relevant to it in considering whether to invest. Each Recipient considering an investment must make, and will be taken to have made, its own independent investigation and analysis of the information in this IPD. Independent expert advice (including from a Recipient's accountant, lawyer or other professional adviser) should be sought before making a decision to invest.

Distribution

This IPD is for selected recipients for purposes of Section 708 of the Corporations Act. It is provided on a strictly private and confidential basis to be used solely by the Recipient. It must not be made available to, or discussed with, any other person without the prior written consent of the Management Team. It is provided to the Recipient solely for its use in connection with providing background information in relation to the Company and the raising of capital and it is not to be used for any other purpose. The distribution of this IPD in jurisdictions outside Australia may be restricted by law and therefore persons into whose possession this IPD comes should seek advice on and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of those laws. This IPD does not constitute an offer of securities in any jurisdiction where, or to any person to whom, it would be unlawful to issue this IPD.

Disclaimer

This IPD and all information (whether in writing or otherwise) which may subsequently be made available to you (**Subsequent Information**) is provided on the terms and conditions set out in this "Important Notice" section. If the terms and conditions set out in this Important Information section are not acceptable to you, then this IPD and any Subsequent Information must be returned immediately to the Company. Retention of this IPD and any Subsequent Information will be deemed to constitute acceptance by you of the terms and conditions set out in this Important Notice section.

No Representations

By submitting an application in response to this IPD, you are deemed to warrant and represent that you do not (and agree that you will not) rely on this IPD, including any forecasts, forward looking statements or prospective financial information contained in the IPD, any Subsequent Information, or any other statement, warranty, representation, express or implied, made by the Company or any of its officers, employees, agents, advisers, consultants or other representatives (**Representatives**) in connection with making a decision about whether or not to invest in the Company.

No Responsibility for Contents of Investor Presentation Document

To the maximum extent permitted by law, no representation, warranty or undertaking, express or implied, is made and, to the maximum extent permitted by law, no responsibility or liability is accepted by any of its directors, officers, employees, agents, promoters or advisers or any other person as to the adequacy, accuracy, completeness or reasonableness of this IPD. To the maximum extent permitted by law, no responsibility for any errors or omissions from this IPD whether arising out of negligence or otherwise is accepted. This IPD contains various opinions, estimates and forecasts which are based upon assumptions which may not prove to be correct or appropriate. Except to the extent implied by law, no representation or warranty as to the validity, certainty or completeness of any of the assumptions or the accuracy of the information, opinions, estimates or forecasts contained in this IPD is made by the Website or any of its directors, officers, employers, agents or advisers.

Accuracy of Projections and Forecasts

All projections and forecasts in this IPD are for illustrative purposes only using the assumptions described in this document. Actual results may be materially affected by changes in economic and other circumstances. The reliance that the Recipient places upon the projections and forecasts is a matter for its own commercial judgment. No representation or warranty is made that any projection, forecast, assumption or estimates contained in this IPD should or will be achieved.

Forward Looking Statements

Any statements of opinion, belief, projections, forecasts or statements relating to expectations in this IPD that constitute statements relating to future acts, events and circumstances are for example only and do not assure the current or future performance of the Company. The Company offers no assurance or guarantee or warranty that those acts, events and circumstances will occur or arise in the manner in which they are portrayed in this document, and investors must be aware that they may not occur or arise in the way in which they are portrayed. No representation is made or assurance given that such statements, views, projections or forecasts are reasonable or correct.

Important Notice.

No Listing
As at the date of this IPD, the Company is not listed on any stock exchange.
While the Company may apply for the listing of its shares on a stock exchange in the future, there is no guarantee that the Company's shares will ultimately be listed on a stock exchange and freely tradeable.

Risk
Investment in the Company is speculative and will involve significant risks, due to the nature of the business of the Company, and,In particular, the nature of the investment it has made and intends to make in the University of Auckland clinical trials. The Company is not a suitable investment for persons unable to sustain a loss of all or part of the sum invested or who require certain or predictable income flows. Investors should have the financial ability and willingness to accept the risks and lack of liquidity that are characteristic of the investment described in this IPD. Neither the Company, nor its Representatives, guarantee the performance of the Company, the return of investment capital, the payment of any particular return or the increase in value of the Company, its assets or your investment. An investment in the Company should be considered speculative in nature.

Professional Advice
Investors should obtain professional investment advice before accepting any offer contained in this IPD. This IPD does not contain all information you may require before deciding whether to invest in the Company. In preparing this IPD, the Company has taken no account of the investment objectives, financial situation and particular needs of any particular person, and prospective investors must not construe the contents of this IPD as tax, legal or financial product advice. Before making any investment decision, prospective investors should seek and rely on their own professional advice, in particular by obtaining appropriate tax, legal, financial and investment advice in light of their own circumstances and conduct their own independent investigation and analysis regarding any information contained in this IPD. This IPD is not, and should not be construed as, a recommendation or advice from the Company or any of its Representatives to consider investing, or to invest, in the Company now or at any time in the future.

Shape Capital Pty Ltd ACN 167 240 637 ("Shape Capital") has not made independent investigation, verification or audit of the information contained in this document and makes no representations or warranties, expressed or implied, regarding the accuracy or completeness of the information contained herein. It accepts no liability to any party and recommends readers hereof not to rely solely on any information, statement or opinion contained in this document, or its accuracy, reasonableness or completeness. This document does not purport to contain all the information that a prospective investor may require. In all cases, interested parties should conduct their own investigation and analysis of the Company and the data contained in this document. To the full extent permitted by law:

(a) no representation or warranty (express or implied) is given; and
(b) no responsibility or liability (including in negligence) is accepted, by the Parties as to the truth, accuracy or completeness of any statement, opinion, forecast, information or other matter (whether express or implied) contained in this document or its attachments or as to any other matter concerning them. To the full extent permitted by law,
(a) responsibility or liability (including in negligence) is accepted by the Parties: for or in connection with any act or omission, directly or indirectly in reliance upon the document; and
(b) for any cost, expense, loss or other liability, directly or indirectly, arising from, or in connection with, any omission from or defects in, or any failure to correct any information, in this document or any other communication (oral or written) about or concerning them, or the issue of securities in the Company.

If you complete an application for Shares or complete a Converting Loan Terms Sheet, you will be providing personal information to the Company. The Company collects, holds and will use that information to assess your application, service your needs as a Shareholder and to facilitate distribution of payments and corporate communications and notification of meetings (via postal service, fax or electronic means) to you as a Shareholder. The information may also be used from time to time and disclosed to persons inspecting the register, such as regulatory bodies, including the Australian Taxation Office; authorised securities brokers; print service providers and mail houses. Collection, maintenance and disclosure of certain personal information is governed by legislation including the *Privacy Act 1988* (Cth) and the Corporations Act. You should note that if you do not provide the information required on the application for Shares, the Company may not be able to accept or process your application.

Confidentiality
You acknowledge and agree that the information contained in this IPD is confidential in nature, other than information which is in the public domain through other means, and that any disclosure or use of such information by you may cause serious harm or damage to the Company. You agree not to reproduce or disclose any information contained in this IPD (or any part of it) to any party, other than to your professional advisers for the purpose of obtaining advice in connection with the details contained in this IPD, without approval in writing from the Company (which may be withheld by the Company in its absolute discretion).

Exclusion of Liability
The Company and the other parties referred to in this IPD do not accept liability for any loss or damage suffered or incurred by you or any other person or entity however caused (including negligence) relating in any way to or arising in any way from this IPD, including (without limitation) the information contained in it, or any errors or omissions. The Company and the other parties referred to in this IPD do not accept any responsibility to inform the Recipient of any matter arising or coming to its notice, which may affect any matter referred to in this IPD. The Company has not authorised any person to make any statements or representations, which are not expressly contained in or contemplated by this IPD. Any liability of the Company and the other parties referred to in this IPD to you or to any other person or entity arising out of this IPD is, to the maximum extent permitted by law, expressly disclaimer and excluded.

Other Important Information
This IPD has been issued by, and contains information concerning the Company. It is provided on a non-transferable basis for your confidential use only. No part of this IPD or any Subsequent Information may be reproduced or used for any other purpose. Some of the information contained in this IPD has been obtained from third parties and has not been independently verified. Accordingly, no representation, warranty or undertaking, express or implied, is made and no responsibility is accepted by the Company as to the accuracy, currency or completeness of any part of this IPD or any supplement to it or any further information supplied by or on behalf of the Company. The Company has furnished the information contained in this IPD and other sources believed by the Company to be reliable. The Company makes no representation or warranty as to the accuracy or completeness of any such information. Neither the Company, nor any of its Representatives (which also includes but is not limited to the persons named or described in this IPD) warrant or represent, either expressly or by implication, that this IPD or any Subsequent Information is complete or has been subject to any audit, examination or verification to confirm its accuracy. This IPD contains summaries, believed to be accurate, of certain terms of certain documents but reference is made to the actual documents, copies of which may be made available if required, for the complete information contained therein. All such summaries are qualified in their entirety by this reference. If you proceed with an investment in the Company, you must rely solely on your own independent review, investigation and analysis. You agree you will not hold the Company or its Representatives liable in any way whatsoever (whether in contract, negligence, equity or otherwise) as a result or by reason of the provision of this IPD or any Subsequent Information to you or any other person. This IPD is not a Product Disclosure Statement or Prospectus; it has not been lodged with ASIC; and is not regulated by Chapter 6D or Part 7.9 of the Corporations Act. This IPD is intended for, and available only to, 'sophisticated' investors, 'professional' investors or other persons to whom an offer of securities for issue may be made without disclosure as a result of the operation of section 708 of the Corporations Act.

MindBio Therapeutics

Blackhawk Growth Corp.

Highlights.

- ✓ Sept 2021 Blackhawk Growth Corp (CSE:BLR) Acquires MindBio Therapeutics
- ✓ Developing Microdosing Therapies to Treat Mental Health Conditions Using Psychedelic Formulations
- ✓ Started Phase 1 LSD Microdosing Clinic Trials for depression
- ✓ Phase 2 LSD Microdosing Clinical Trials for Cancer patients approved
- ✓ Trials conducted by The University of Auckland
- ✓ World Class Research Team
- ✓ New Zealand Government Grants - $845,844
- ✓ Minister of Health – Regulatory Approval
- ✓ Approval for patients to self administer drug at home
- ✓ Approved Import License

Tier 1 Academic Institution in New Zealand

Overview.

- MindBio Therapeutics is pioneering research into the clinical use of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions.

- On 1 September 2021 Blackhawk Growth Corp (CSE:BLR), a Canadian Securities Exchange listed investment company acquired 100% of MindBio Therapeutics.
  - The acquisition proposes to bring together and leverage existing psychedelics assets and capabilities within the Blackhawk group.

- The Company is a global leader in **microdosing therapies.**

- **In New Zealand and some parts of Europe such as the Netherlands, the approvals for testing compounds such as LSD have been more progressive with government approvals and supportive health department funding.**

- MindBio Therapeutics is advancing clinical research to accelerate the potential commercialization of treatment options using psychedelics and is sourcing a range of tier 1 research projects and clinical trials.

- MindBio Therapeutics has signed a binding term sheet with the University of Auckland, in New Zealand, for the funding of microdosing clinical trials and commercialization of all intellectual property.

- In April 2021, Phase I clinical trials started at the Medical and Health Sciences School of Pharmacy at the University of Auckland in New Zealand to determine the effectiveness of microdosing Lysergic Acid Diethylamide (LSD) for treating depression.

MindBio Therapeutics

Market Capitalization by Competitor

Green Clinical Trials underway, Red No Clinical Trials

Blackhawk Growth Corp.

Symbol	Company	Market Cap	Phase 1 Clinical Trials	Phase 2 Clinical Trials	Phase 3 Clinical Trials
ATAI	ATAI Life Sciences N.V.	$ 2,605,616,830	5 Phase 1 Clinical Trials Underway	2 Phase 2 trials in planning	
CMPS	COMPASS Pathways Plc	$ 1,386,786,842	1 Phase 1 Clinical Trial in 89 people Completed	1 Phase 2b clinical trial underway	
GHRS	GH Research PLC	$ 1,100,344,113	1 Phase 1 Clinical Trial completed, 1 other underway1 phase 2 clinical trial underway		
MNMD	Mind Medicine (MindMed) Inc.	$ 906,672,227	Circa 4 Phase 1 Clinical Trials underway	1 Phase 2 clinical trial LSD in anxiety, 1 phase 2b feasibility LSD pain	
CYBN:AQL	CYBIN INC.	$ 484,210,287		1 Phase 2A clinical trial and 1 Phase 2B clinical trial underway	
FTRP:CA	Field Trip Health Ltd.	$ 379,674,482	Phase 1 in planning		
GDNS:CNX	Goodness Growth Holdings Inc. Subordinate Voting Shares	$ 222,378,600			
SEEL	Seelos Therapeutics Inc.	$ 221,000,849	Phase 1 complete	Phase 2 in progress	
NUMI:CA	Numinus Wellness Inc.	$ 172,540,078	2 Compassionate Access Trials Underway		1 phase 3 compassionate access trial
CBDT:CNX	Empower Clinics Inc.	$ 141,696,074			
MYCO:AQL	MYDECINE INNOVATIONS GROUP INC.	$ 105,021,993	Just signed agreement with John Hopkins University	Phase 2a in progress	
ALID	Allied Corp	$ 84,324,310	Phase 1 in progress		
TRIP:CNX	Red Light Holland Corp. - Common Shares	$ 83,222,191			
RVV:CNX	Revive Therapeutics Ltd - Ordinary Shares	$ 74,816,467			
PHRM:CNX	PharmaTher Holdings Ltd Com	$ 70,432,214	Phase 1/2 in progress	Phase 1/2 in progress	
MSET:CNX	Mindset Pharma Inc.	$ 70,049,315			
DRUG:CNX	Bright Minds Biosciences Inc.	$ 69,942,330			
FH:AQL	FILAMENT HEALTH CORP.	$ 55,994,385			
OPTI:CNX	Optimi Health Corp.	$ 46,490,567			
ENVB	Enveric Biosciences Inc.	$ 45,008,072	Approved for phase 1/2 clinical trials	Approved for phase 1/2 clinical trials	
AWKN:AQL	AWAKN LIFE SCIENCES CORP.	$ 44,329,568		2 clinical trials at Phase 2	
BRAX:CNX	Braxia Scientific Corp Com	$ 42,144,629	Approved to commence clinical trials		
MEDI:AQL	KETAMINEONE CAPITAL LIMITED	$ 41,933,565			
WESA:CNX	Wesana Health Holdings Inc.	$ 40,252,790			
MCUR:CNX	Mind Cure Health Inc.	$ 35,666,475			
NM:CNX	Novamind Inc.	$ 33,366,637			
CURR	CURE Pharmaceutical Holding Corp	$ 32,727,978			
HAVN:CNX	HAVN Life Sciences Inc.	$ 31,477,509			
TRYP:CNX	Tryp Therapeutics Inc.	$ [illegible]			
BLR	Blackhawk Growth Corp	$ 29,911,053	1 Phase 1 Clinical Trial Underway	1 Phase 2 trial approved, 3 Phase 2 trials in planning	
WUHN	M2Bio Sciences Inc	$ [illegible]			
COOL:CNX	Core One Labs Inc.	$ 27,943,455			
CMND:CNX	Clearmind Medicine Inc.	$ 26,887,000	Unknown		
PSYB:CA	Psybio Therapeutics Corp.	$ 24,468,397			
BETR:CNX	BetterLife Pharma Inc.	$ 22,477,743			
PWR:CNX	Captiva Verde Wellness Corp.	$ 20,806,205			
ENBI:CNX	Entheon Biomedical Corp.	$ 20,264,725			

Competitors with Clinical Trials

MindBio Therapeutics

Blackhawk Growth Corp.

THE UNIVERSITY OF AUCKLAND
NEW ZEALAND

Unique Microdosing Trials.

- "Microdosing" refers to repeated administration of psychedelics such as LSD or psilocybin in doses below the threshold for overtly altering perception.
- In its first approved microdosing study, the University is conducting a randomised controlled trial of repeated microdoses of LSD under schedules similar to those suggested in the grey literature.
- 80 healthy volunteers will be randomised to receive repeated doses of either inactive placebo or LSD (10 µg oral) under double-blind conditions in a parallel groups design.
- A variety of physiological and psychological measures will be recorded at baseline and after completion of each of a six-week dosing regimen.
- Measures will include a validated personality scale and tests of creativity. Electroencephalography will be used to directly measure brain function in each participant before and after treatment.
- Results of the study will enable a rigorous evaluation of the purported benefits of psychedelic microdosing and will be relevant to the question of whether microdosing may be a viable alternative treatment regimen for depression, where full psychedelic doses are currently being investigated in clinical trials.

First candidate: LSD Lysergic acid diethylamide (LSD). Phase 1 Trials underway



LSD molecule

- LSD is thought to bind most serotonin receptor subtypes (1A, 2A, 2C, 5C, and 6) and has activity at dopamine and adrenergic receptors.
- Mood altering effects of LSD are thought to be due to **partial agonism** of the 5-HT_{2A}.
- LSD microdosing is long suggested in the 'grey' literature to improve mood and relieve depression.
- There are some controlled scientific studies on the effects of repeated self-administered micro-dosed LSD.
- LSD is probably the best candidate for microdosing due its long-acting activity at $5HT_{2A}$ receptor.

LSD Microdoses makes people *feel sharper*, and scientist want to know why.

IP Development Pathway.

LSD Microdosing

R&D

Formulation

LSD microdosing formulation for home use

Anti-Tampering Dispensing Device

Prevent misuse or overdosing for drug administration at home

Software Applications

Deep learning applications

MindBio Therapeutics

Anti-tampering & Dose Monitoring Device.

The design, development and trial of a patented anti-tampering and dose monitoring device is intended as part of the clinical trials.

The anti-tampering technology may be also used for dispensing medications for other conditions.

Anti-Tampering Device	Safety Features	Unique Identifier

MindBio Therapeutics

Anti-tampering & Dose Monitoring Device.

Wearables

- Monitor physiological, psychological and cognitive activities
- Accurately capture and predict clinical outcome/treatment responders
- Individualize dosing and schedule for optimal treatment results

Oral Formulations

- An LSD microdosing formulation for home use

Digital Applications

- Data collection
- Deep learning algorithms
- Patient – doctor communication and monitoring
- Biomarker development and precision diagnosis

Real World Testing of dispensing and delivery solutions

MindBio Therapeutics is interested in developing novel drug formulations, prescription and dispensing and drug delivery solutions. The New Zealand regulatory framework allows home dosing by study subjects. The clinical trial provides an opportunity to test a variety of safe delivery and monitoring technologies for use in the real world.

Global Mental Health Statistics.

In United States

- 19% of Adults experience a mental illness[1]
- Suicidal ideation among adults increased 0.15%[1]
- 24% of adults with a mental illness report an unmet need for treatment[1]

In Australia

- 11.6% of the population are currently experiencing depression or anxiety[3]
- 12.5% of the population are taking an anti-depressant



[1] https://mhanational.org/issues/state-mental-health-america
[2] https://www.who.int/teams/mental-health-and-substance-use/suicide-data
[3] https://www.beyondblue.org.au/home

Microdosing psychedelics may offer:

- Potential lower side effect risk profile to existing pharmacological treatments for the treatment of a range of mental health conditions.
- Less risk of harm than large, one off doses of psychedelics where most of the current emphasis in research has been focused.
- Brain neuroplasticity effects:
    - Activating parts of the brain not seen in traditional medications such as SSRIs and Benzodiazapines.
    - Elimination of rumination and worry patterns seen in anxiety and depression.
- Improved response to psychotherapy whilst using psychedelics.
- Faster treatment/response times.
- Safe alternatives to the existing accepted regimes of anti-depressant and anti-psychotic medications.
- Potential new hope to chronic sufferers of mental health conditions where existing treatments have failed.

MindBio Therapeutics

Regulatory Environment.

- The “Scheduling” or restriction of psychoactive drugs has limited the extent to which research has been able to occur into their clinical use and effectiveness.
- Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and methylenedioxymethamphetamine ("Ecstasy").
- In Australia, psychedelics are classified as a Scheduled 9 drug, meaning it is a prohibited substance. However, the federal government in Australia recently has side stepped the Therapeutic Goods Administration’s classification and allocated $15 million to fund research into their clinical use.[1]
- **In New Zealand, LSD is a Schedule I Class A controlled drug, however the minister has approved it’s use for the University of Auckland clinical trial via an exemption provided in Section 8, Misuse of Drugs Act[2]**

[1] https://www.smh.com.au/politics/federal/better-treatments-government-to-fund-psychedelic-drugs-trials-to-treat-mental-illness-20210316-p57b7i.html

[2] https://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436242

Scheduling of drugs in USA, United Nations countries and United Kingdom

Substance	United Nations conventions	UK Misuse of Drugs Regulations	UK Misuse of Drugs Act	US Controlled Substances Act
Amphetamine	Schedule II (1971)	Schedule 2	Class B	Schedule II
Cannabis and cannabis resin	Schedules I and IV (1961)	Schedule 1	Class B	Schedule I
Cannabidiol	Not listed	Not listed	Not listed	Not listed
Cocaine	Schedule I (1961)	Schedule 2	Class A	Schedule II
2-bromo-LSD	Not listed	Schedule 1?	Class A? (uncertain)	Not listed
Heroin (also known as diamorphine)	Schedule I (1961)	Schedule 2	Class A	Schedule I
Ketamine	Not listed	Schedule 4	Class C	Schedule III
LSD (also known as lysergide)	Schedule I (1971)	Schedule 1	Class A	Schedule I
MDMA (also known as ecstasy)	Schedule I (1971)	Schedule 1	Class A	Schedule I
Methamphetamine	Schedule II (1971)	Schedule 2	Class A	Schedule II
Methoxetamine	Not listed	Schedule 1	Class B	Not listed
Psilocybin	Schedule I (1971)	Schedule 1	Class A	Schedule I
THC (also known as dronabinol)	Schedule II (1971)	Schedule 2	Class B	Schedule III
THCV	Not listed	Schedule 1	Class B	Not listed

The UK Misuse of Drugs Act (1971) categorizes drugs into three classes according to harms (A>B>C) and these determine the penalties for possession (7 >5>3 years in prison, respectively) or supply (life>14>14 years, respectively). In the United States, the situation is more complex, in that each drug has its own level of penalties applied. The United Nations conventions and the US Controlled Substances Act use roman numerals for the Schedules (that is, I, II, and so on), whereas the UK Misuse of Drugs Regulations use Arabic numerals (that is, 1, 2, and so on). LSD, lysergic acid diethylamide; MDMA, 3,4-methylenedioxy-*N*-methylamphetamine; THC, Δ^9-tetrahydrocannabinol; THCV, tetrahydrocannabivarin.

Source: Effects of Schedule I drug laws on neuroscience research and treatment innovation. David J. Nutt, Leslie A. King and David E. Nichols

Regulatory Environment – Favorable Legal and Clinical Framework.

MindBio Therapeutics Competitive Advantage



In New Zealand LSD is a Schedule I, Class A controlled drug.

Under S22 of the Misuse of Drugs Regulations 1975:

- Minister's approval has been obtained for the clinical trial
- Import licenses have also been obtained

Real World Use case & clinical testing

- Medical practitioner prescribes the drug
- Patient may administer drug at home, **(a substantial clinical trial advantage)** for real world outcomes

Government, Academic and Community Support.

World-first LSD trial in Auckland could open door to its use as medicine

20 Aug, 2019 05:00 AM

Suresh Muthukumaraswamy, from the Auckland University School of Medicine, was involved in a couple of th most important recent psychedelic studies. Photo / Greg Bowker

By: **Derek Cheng**

Derek Cheng is a political reporter for the New Zealand Herald

derek.cheng@nzme.co.nz

Psychedelics on trip back from fringe

21 April 2020 | The Challenge, Future of health and wellbeing, Faculty of Medical and Health Sciences

LSD and ketamine are illegal drugs. They also hold new hope for people with depression and addictions resistant to current therapy.

Suresh Muthukumaraswamy: Investigating psychedelic drugs for depression and serious addictions.

MindBio Therapeutics

Regulatory Approvals – Phase 1 LSD Clinical Trial Approved and Underway.

The clinical trial protocols were published in advance of data collection [2]. Trials Started in April 2021. The trial is registered on the Australian New Zealand Clinical Trials Registry [1].

Scientific Title

A randomised, double-blind, placebo-controlled trial to study the effects of repeated microdoses of lysergic acid diethylamide (LSD) on creativity and brain activity in healthy adult males.

- There is a growing microdosing subculture and grey literature suggesting that this practice can enhance creativity and productivity, Improve mood and favourably modify personality traits.
- These classified effects are similar to those observed in clinical studies, in which participants receive much larger, perception-altering doses of LSD or psilocybin. Currently there are no controlled, scientific studies of the psychological or physiological effects of repeated psychedelic home-self-administered microdosing.

Microdosing Study Has Been Approved

1. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=381476&isReview=true
2. https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05243-3

Regulatory Approvals – Phase 2 LSD Clinical Trial Approved in Cancer Patients.

The Phase 2 LSD microdosing trial in cancer patients has just been approved and a $250,000 grant provided by the New Zealand Ministry of Health[1].

Summary

The administration of high-dose psychedelic compounds have shown clinically significant benefits in the treatment of psychological distress in advanced cancer patients. However, psychedelics at high doses can vividly alter perceptions; an experience that poses challenges in this vulnerable population. 'Microdosing' – repeated administration of psychedelics in low doses does not alter perceptions but may offer similar benefit in reducing anxiety, depression and existential distress. This study will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted – Meaning Centred Psychotherapy to standard Meaning-Centred Psychotherapy in people who have advanced cancer and anxiety or depression. Participants will be randomised to receive psychotherapy alongside doses of either an LSD microdose or placebo. The feasibility, acceptability, safety and potential psychological benefits of this intervention will be assessed. Our findings will inform the development of a larger trial and provide initial indication of potential benefits of psychedelic microdosing in advanced cancer.

Microdosing Study Has Been Approved

1. https://hrc.govt.nz/resources/research-repository/psychedelic-assisted-therapy-advanced-stage-cancer-patients

Clinical Outcomes Measured.

Phase 1 study of LSD microdosing for home use

- Personality traits assessed by NEO-PI-R
- Creativity assessment (alternate uses test, picture concept tasks)
- Measures of cortical plasticity (MMN, LTP paradigms, EEG) and cortical connectivity (fMRI)
- Mood assessment (NIH Toolbox emotion battery)
- Cognition assessment (NIH Toolbox cognition battery)
- Basic physiological measures (heart rate, blood pressure, sleep, activity tracking)

Clinical Pathway.

18-24 Months

Formulation Development

9-12 Months

GMP Manufacturing of Product for Clinical Trials

18-24 Months

Anti-Tampering Safety Device Development

18-24 Months

App/Biomarker Development - Precision Prognosis

0 – 9 Months

Phase 1 Safety Study

Milestone/Objective :

- Phase 1 study complete.
- Clinical pathway established.

12 - 25 Months

Phase 2a Studies- Target Indications:

- Depression
- Chronic Pain
- Mild Cognitive Impairment

Milestone/Objective :

- Phase 2a study complete.

24 to 48 Months

Phase 2/3 Studies-Target Indications:

- Depression
- Chronic Pain
- Mild Cognitive Impairment

Milestone/Objective :

- Phase 3 study complete.

Commercialization

Government Grant & Support.

Health Research Council of New Zealand Grants

$845,844 Awarded

The New Zealand government has recognized the substantial cost of mood disorders and provided funding to University of Auckland Microdosing Study in the amount of **$596,511.55.** A second grant of **$249,333** has just been awarded in July 2021.

Summary of Grant purpose

"Mood disorders are a leading cause of health loss in New Zealand, however, current treatments do not work or are not well tolerated by large number of people who suffer from these disorders. Increasing evidence from animal studies and anecdotal reports suggest that low doses of serotonergic 2A receptor agonists are able to positively Improve symptoms of depression and anxiety. However, this has yet to be adequately tested in humans. In this research we will conduct a randomised control clinical trial using repeated low doses of a serotonergic 2A receptor agonist in healthy human volunteers. We will assess its effects on mood, cognition, and brain function as a key step before testing in a clinical patient group. Conducting a healthy volunteer trial is a critical step before conducting future clinical trials in patients with depression and anxiety".

Microdosing Product Pipeline.

Microdosing Clinical Trials



*Clinical Trials pipleline assumes the required capital is raised in subsequent funding rounds

Research Team.

Dr Suresh Muthukumaraswamy
PhD BSc Hons
Lead Scientist.
Associate Professor.

Suresh is an Associate Professor of Psychopharmacology in the Faculty of Medical and Health Sciences at the University of Auckland.

Suresh's main research interests are in understanding how therapies alter brain activity and in developing methodologies to measure these changes in both healthy individuals and patient groups – particularly those with depression. His previous studies have involved a range of compounds including hallucinogens (ketamine, LSD, psilocybin), anesthetics (propofol, dexmedetomidine), anti-epileptics (vigabatrin, perampanel, tiagabine) and GABA-enhancers (zolpidem, gaboxadol).

He is currently leading clinical trials investigating LSD microdosing and other new antidepressant therapies. Suresh has published over 100 scientific papers in the field of psychopharmacology and neuroimaging which have been cited over 6500 times. Suresh has received several awards including a prestigious Rutherford Discovery Fellowship and several grants from the Health Research Council of New Zealand.

Research Team.

Dr Frederick Sundram PhD. MSc. MA. FRCPsych(UK). MB BCh. BAO; B.MedSc.

Associate Professor Psychiatry/ Health Technology

Frederick is an Associate Professor at the Department of Psychological Medicine at the University of Auckland and a Consultant Liaison Psychiatrist at North Shore Hospital. Previously he was research fellow at the Department of Forensic and Neurodevelopmental Science at the Institute of Psychiatry, King's College London and the Royal College of Surgeons in Ireland where he completed his PhD in Neuroimaging. Frederick also completed a Masters in Healthcare Management at the Institute of Public Administration, Dublin and a Masters in Healthcare Informatics. His research interests include depression, neuroimaging, self-harm/suicide, medical education, overlap between medicine and psychiatry, medically unexplained physical symptoms and healthcare informatics.

Dr Darren Svirskis

Associate Professor. PhD.BHB. BPharma.

Professor Svirskis is an Associate Professor of Psychopharmacology in the Faculty of Medical and Health Sciences at the University of Auckland. He is a pharmacy lecturer in the faculty and is primarily interested in the use of materials to communicate with and influence the body through microelectrode arrays and the intelligent delivery of drugs.

Dr Nicholas Hoeh MD.Am.BD Cert Psych

Consultant Psychiatrist

Nick is a consultant psychiatrist working part time at the Auckland District Health Board and in private practice. Additionally, he is a professional teaching fellow in Psychological Medicine at the University of Auckland. He obtained his medical degree at the University of Medicine and Dentistry in New Jersey and completed his internship, psychiatry residency, and old age psychiatry fellowship at the University of Pennsylvania in Philadelphia. Nick's current research interests include the clinical use of repetitive transcranial magnetic stimulation and psychedelics for treatment resistant depression.

Dr Partha Roop PhD; M.Tech; BEng.

Associate Dean (International) Faculty of Engineering
University of Auckland

Partha's research interests are in Digital Health, Formal Methods for Safety-Critical applications of AI and Machine Learning, and Real-Time Systems. Partha is working with colleagues from the Medical School and the Auckland Bioengineering Institute (ABI) on new techniques developed by his group known as organ on a chip. He is also interested in heart rate variability and Biofeedback.

Dr Rachael Louise Sumner PhD.Pharma. MSc Hons. BA. Hons. Psychology.

Research Associate. Dr Sumner is a leading researcher in the field of psychedelics and has been involved in numerous research studies in her work at the University of Auckland. Notable studies include the use of Ketamine in the treatment of depression and the overarching aim and application of Dr Sumner's research is to validate non-invasive electrophysiological assays of brain function in neurological and psychiatric health and disease.

Board of Directors.

Gavin Upiter.

Non-Executive Chairman

Gavin has over 25 years of experience leading companies in the pharmaceutical sector. Engineering qualified, prior to founding Generic Health, a leading generic pharmaceutical company which was sold to Lupin Pharmaceuticals (NSE:LUPIN), Gavin started his executive career at Bristol Myers Squibb. He was Australian CEO of Amneal Pharmaceuticals (NYSE: AMRX) and Executive Director of Slade Health, Australia's leading hospital pharmacy chain. Gavin founded Directo, Australia's first online pharmaceutical B2B marketplace for pharmacies and suppliers.

Dr Zena Burgess

Non-Executive Director

Zena currently serves as the Chief Executive Officer of the Australian Psychologists Society and formerly as Chief Executive of the Royal Australian College of General Practitioners. With a strong interest in futures of health care, Zena is a member of the international advisory board of Connext2MyDoctor and the telehealth influencers alliance. She is also a director of the Australian Patients Association and Chair of the board subcommittee on governance and risk of the Victorian Farmers Federation. Zena has substantial experience serving on boards of government entities. She holds a PhD in psychology from the Australian Catholic University and a Master of Business Administration from Monash University and a Master of Education from La Trobe University. She has a wealth of experience in health changes and strategic advocacy to governments.

Colin Keating

Chief Executive Director

Colin was CEO of BuyMyPlace, previously listed on Australian Securities Exchange, (ASX:BMP) and managing director of UK listed Hogg Robinson Group (LON: HRG), sold to American Express . Colin possesses a demonstrable track record in driving growth, shaping organisational culture and delivering shareholder value. Colin has over 25 years experience scaling companies across various industries including Financial Services & Payments, Corporate Travel, Property Tech, Health Tech and Wealth Management.

Justin Hanka

Director & Co-Founder

Justin is a corporate advisor and works in investment banking and financing of mergers and acquisitions and capital markets transactions. He is Non-Executive Director of EonX (CSE:EONX), a financial technology company, Non-Executive Director of Goldcar, a Europcar Company (XPAR:EUCAR), Non-Executive Director of The Digital Tribes Company, an IT digital transformation company based in Sweden. He is an experienced executive having served as Chief Operating Officer for iSelect (ASX: ISU) and having sold Helpmechoose as its CEO to listed Mortgage Choice (ASX:MOC). Justin's expertise spans the pharmaceutical and health sector, fin-techs, digital transformation and technology, influencer marketing, insurance, health and wellness, entertainment and ecommerce.

Contact.

Investment queries:

Shape Capital Pty Ltd
Level 8, 90 Collins Street,
Melbourne VIC 3000

Contact: Anoosh Manzoori
P: +61.409 252 088
E: anoosh@shape.capital
W www.shape.capital